Fidelio Capital partners with Alphalyse
Alphalyse has entered into a new partnership with the Swedish investment firm Fidelio Capital, which has acquired the majority stake in the company. The goal is to accelerate international growth and strengthen Alphalyse’s position as a global frontrunner in mass spectrometry-based analysis of biologic drugs. The two founders, Ejvind Mørtz and Thomas Kofoed, retain a significant ownership stake and will continue in the company’s leadership.
The collaboration aims to expand capacity, create new jobs in Odense, and strengthen the company’s partnership with the University of Southern Denmark. The partnership comes at a time when precise and detailed analysis of protein impurities is becoming increasingly important in the development and approval of modern biologic drugs.
As part of the investment, Torben Frigaard Rasmussen is stepping down as Chairman of the Board. He highlights Alphalyse as a groundbreaking player with the potential to deliver better medicines, faster, and sees the partnership with Fidelio as a key to scaling the technology globally – benefiting both the company and the growing life science cluster in Odense.